Eur Heart J:心血管事件高危的高血压患者,血压应控制在140/90mmHg?还是130/80mmHg?

2015-11-28 phylis 译 MedSci原创

目的:最近高血压指南建议,心血管事件(CV)风险较高的高血压患者,应将血压降低到140/90mmHg,先前指南支持高血压目标值降至130 / 80 mmHg。然而,这是否是最佳的治疗策略尚有争议。方法和结果:长期应用缬沙坦抗高血压评估试验中,将CV高危的高血压患者分为亚组:(i) 治疗随访期间BP降至140/90或<130 / 80 mmHg的百分比,或(ii) 整个治疗期间平均收缩压或舒张压(S

目的:最近的高血压指南建议,心血管事件(CV)风险较高的高血压患者,应将血压降低到140/90mmHg,但是先前指南支持的目标值是降至130 / 80 mmHg。因此,140/90mmHg是否是最佳的治疗策略尚有争议。

方法和结果:长期应用缬沙坦抗高血压评估试验中,将CV高危的高血压患者分为亚组:(i) 治疗随访期间BP降至140/90或<130 / 80 mmHg的百分比,或(ii) 整个治疗期间平均收缩压或舒张压(SBP/DBP)或者高至事件发生。

随访期间BP<140/90mmHg的百分比从<25 增至≥75%, CV事件的发生率及死亡率、特定CV事件的发生(心肌梗死、心衰及卒中)、各种原因的死亡率显著下降。BP<130/80mmHg的随访百分比进行性增加,除了卒中发生下降增加,其他事件的发生未见显著性下降增加。

校正基线风险差异后,BP<140/90mmHg(而不是BP<130/80mmHg)随访的百分比增加与事件发生下降相关。最后,与治疗时平均SBP≥140或DBP≥90mmHg相比,平均SBP为130-139或DBP为80-89mmHg的患者所有事件发生的风险显著下降,然而,治疗SBP <130 mmHg 或DBP <80 mmHg时,卒中发生的风险下降增加,其他事件的发生并未下降增多,与较高血压控制组相比,其他事件发生的风险相似,或者仅有轻度的升高。

结论:CV高风险的高血压患者,不管是按照随访BP目标值的比例或按照治疗时的平均血压值,将BP控制连续降低至<140/90益处显著增加。将BP值降至130/80 mmHg仅使卒中发生的风险降低增加,其他预后发生的风险相似或轻度升高。因此,除了患者卒中发生风险较高时,CV高危的患者BP控制降低的增加可能并未增加潜在的优势。

原文出处:

Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2015, Nov 20.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643389, encodeId=c51e16433893c, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 30 21:38:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356037, encodeId=ce29135603eb3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448152, encodeId=138014481521d, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562339, encodeId=8a321562339d7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643389, encodeId=c51e16433893c, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 30 21:38:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356037, encodeId=ce29135603eb3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448152, encodeId=138014481521d, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562339, encodeId=8a321562339d7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=)]
    2015-11-30 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643389, encodeId=c51e16433893c, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 30 21:38:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356037, encodeId=ce29135603eb3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448152, encodeId=138014481521d, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562339, encodeId=8a321562339d7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643389, encodeId=c51e16433893c, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 30 21:38:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356037, encodeId=ce29135603eb3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448152, encodeId=138014481521d, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562339, encodeId=8a321562339d7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Nov 30 06:38:00 CST 2015, time=2015-11-30, status=1, ipAttribution=)]
    2015-11-30 slcumt

相关资讯

SPRINT试验结果公布,高血压市场骤然膨胀

在今天进行的美国心脏病协会年会上由NIH资助的高血压实验SPRINT结果正式公布,同时在NEJM上发表,并伴随发表三篇评论,显示业界对此实验的重视。这个实验招募了9361名50岁以上、血压130毫米汞柱以上、没有糖尿病的患者。严格控制组一年后血压控制在121.4毫米,标准组在136.2毫米。随访3.26年后因疗效显着提前终止,结果120毫米组全因死亡155人,心血管死亡37人,而140毫米组分

BMC Med:肾髓质肾素受体降低AngⅡ介导的高血压

中山大学医学院高血压研究所Fei Wang和同事研究发现肾髓质肾素受体通过激活局部肾素-血管紧张素系统降低大鼠血管紧张素Ⅱ介导的高血压。研究结果2015年11月10日于BMC Medicine在线发表。

NEJM:提前终止的惊世高血压SPRINT研究正式发表,但争议仍在继续

NEJM:提前终止的惊世高血压SPRINT研究正式发表,但争议仍在继续多年来,关于高血压患者的血压(BP)应降低到什么程度的问题一直存有争议。现在多中心收缩压干预试验(SPRINT)终于为临床医生提供了一些有意义的指导。此项SPRINT共纳入了 9361名收缩压在130-180 mm Hg的患者(年龄≥50岁),为心血管(CV)疾病的高危人群(定义为:已患有症状或无症状CV疾病和/或慢性肾病(CK

J Hypertens:高血压增加亚洲中年人群卒中发生的风险

背景:终生风险(LTR)阐明余生患病的可能性。这些评估增加一般人群对控制高血压的了解。因亚洲人群卒中风险高于西方人群,这仅是一些有关高血压对亚洲人群卒中事件影响的报道, 方法:这项在日本进行的心血管事件疾病的队列研究始于1989年。研究者选取未发生卒中的人群作为受试者。年龄(年)被作为时间尺度。以10年尺度每人每年的方法计算年龄特异发病率。将死亡作为竞争风险,研究者评估了首发卒中患者不同性别和年龄

Clin Res Cardiol:NT-proBNP可预测无症状性高血压和糖尿病患者的预后

背景:无症状性高血压和无临床心衰(HF)症状的糖尿病患者钠尿肽和临床预后之间的关系尚不清楚。在无症状,A / BHF高血压和糖尿病患者中,研究者评估了N端脑钠肽前体(NT-前BNP)的预测价值,及与年龄和性别之间的关系。方法:检测了1012名高血压和/或无HF心衰症状的糖尿病(66.6±7.8岁,48%为男性)无症状患者NT-proBNP。对患者进行前瞻性随访超过49.8±6.7个月,主要随访患者

Atherosclerosis:原发性高血压伴发代谢综合症影响心血管事件的发生

背景:高血压患者普遍存在代谢综合症(MS)。然而,MS对动脉粥样硬化事件的影响是否超过个别组成对心血管事件的影响尚有争议。研究者旨在评估高血压人群中MS对不良心血管事件的独立预测作用。方法:研究者随访了2176名原发性高血压患者,这些患者不存在心血管疾病,随访时间中位数为40个月。对所有受试者进行至少一年一次随访。根据更新的NCEP III 标准定义MS。主要终点为卒中发生,冠心病(CAD)发生或